AnaptysBio, Inc. (NASDAQ:ANAB) Given Average Rating of “Moderate Buy” by Brokerages

Shares of AnaptysBio, Inc. (NASDAQ:ANAB) have been assigned a consensus recommendation of “Moderate Buy” from the eleven research firms that are covering the company, MarketBeat reports. One equities research analyst has rated the stock with a sell recommendation, one has assigned a hold recommendation and nine have issued a buy recommendation on the company. The average twelve-month price target among brokerages that have updated their coverage on the stock in the last year is $73.4444.

Several research firms have recently commented on ANAB. Truist Financial set a $50.00 target price on AnaptysBio in a research report on Friday. Wall Street Zen cut AnaptysBio from a “strong-buy” rating to a “buy” rating in a report on Friday, January 23rd. UBS Group assumed coverage on AnaptysBio in a research note on Wednesday, January 7th. They issued a “buy” rating and a $70.00 price target for the company. Weiss Ratings reiterated a “sell (d-)” rating on shares of AnaptysBio in a research report on Wednesday, January 21st. Finally, HC Wainwright boosted their target price on shares of AnaptysBio from $51.00 to $66.00 and gave the company a “buy” rating in a research report on Wednesday.

AnaptysBio Stock Performance

Shares of ANAB stock opened at $55.41 on Friday. AnaptysBio has a 52 week low of $15.32 and a 52 week high of $63.47. The company has a market capitalization of $1.59 billion, a price-to-earnings ratio of -106.56 and a beta of 0.32. The company has a 50-day simple moving average of $50.27 and a 200 day simple moving average of $39.03.

AnaptysBio (NASDAQ:ANAB) last released its quarterly earnings results on Monday, March 9th. The biotechnology company reported $1.58 earnings per share for the quarter, beating the consensus estimate of $0.89 by $0.69. The firm had revenue of $108.25 million for the quarter, compared to analysts’ expectations of $87.09 million. AnaptysBio had a negative net margin of 5.64% and a negative return on equity of 1,101.24%. Sell-side analysts forecast that AnaptysBio will post -6.08 EPS for the current year.

AnaptysBio announced that its board has initiated a share buyback plan on Friday, November 21st that allows the company to repurchase $100.00 million in shares. This repurchase authorization allows the biotechnology company to buy up to 9.6% of its shares through open market purchases. Shares repurchase plans are generally a sign that the company’s leadership believes its stock is undervalued.

Key Headlines Impacting AnaptysBio

Here are the key news stories impacting AnaptysBio this week:

• Positive Sentiment: Stifel Nicolaus raised its price target sharply to $85 and kept a buy rating — a sizable upside vs. recent levels that likely boosted investor demand. Stifel raises PT to $85
• Positive Sentiment: Coverage noting a profitability turnaround and continued progress collecting Jemperli royalties supports a higher valuation narrative for ANAB. This fundamental story likely underpins recent buying interest. Assessing AnaptysBio valuation after profitability turnaround
• Positive Sentiment: ANAB hit a new 12‑month high following analyst upgrades, which can attract momentum and technical buying. ANAB hits new 12‑month high on analyst upgrade
• Negative Sentiment: HC Wainwright issued a mixed set of estimate changes: it lowered near‑term FY2026 and Q1/Q2 EPS forecasts (worse near‑term profitability) even as it raised several multi‑year estimates; the negative near‑term revisions could pressure sentiment despite the firm’s buy rating and $66 target. HC Wainwright estimate changes (MarketBeat summary)
• Neutral Sentiment: Short‑interest entries in recent reports are inconsistent/zero (showing NaN increases), indicating unreliable short‑interest data — not a clear driver of today’s move. (No reliable link provided in the filings.)

Insider Buying and Selling at AnaptysBio

In related news, CFO Dennis Mulroy sold 15,725 shares of the business’s stock in a transaction that occurred on Tuesday, December 16th. The stock was sold at an average price of $44.85, for a total value of $705,266.25. Following the completion of the sale, the chief financial officer directly owned 9,401 shares in the company, valued at approximately $421,634.85. The trade was a 62.58% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is accessible through this link. Also, insider Eric J. Loumeau sold 12,500 shares of the stock in a transaction that occurred on Tuesday, December 16th. The stock was sold at an average price of $44.86, for a total value of $560,750.00. Following the sale, the insider directly owned 9,088 shares in the company, valued at $407,687.68. This represents a 57.90% decrease in their position. The SEC filing for this sale provides additional information. In the last quarter, insiders have sold 156,280 shares of company stock worth $7,254,939. 33.50% of the stock is currently owned by company insiders.

Hedge Funds Weigh In On AnaptysBio

Hedge funds and other institutional investors have recently added to or reduced their stakes in the stock. Smartleaf Asset Management LLC grew its holdings in shares of AnaptysBio by 5,864.3% during the 4th quarter. Smartleaf Asset Management LLC now owns 835 shares of the biotechnology company’s stock valued at $40,000 after purchasing an additional 821 shares during the last quarter. Larson Financial Group LLC lifted its stake in AnaptysBio by 54.6% in the 3rd quarter. Larson Financial Group LLC now owns 1,340 shares of the biotechnology company’s stock valued at $41,000 after purchasing an additional 473 shares during the last quarter. Mirae Asset Global Investments Co. Ltd. lifted its stake in AnaptysBio by 24.3% in the 4th quarter. Mirae Asset Global Investments Co. Ltd. now owns 1,345 shares of the biotechnology company’s stock valued at $65,000 after purchasing an additional 263 shares during the last quarter. Bessemer Group Inc. boosted its position in AnaptysBio by 950.0% in the third quarter. Bessemer Group Inc. now owns 1,428 shares of the biotechnology company’s stock valued at $44,000 after buying an additional 1,292 shares in the last quarter. Finally, Caitong International Asset Management Co. Ltd grew its stake in shares of AnaptysBio by 940.8% during the fourth quarter. Caitong International Asset Management Co. Ltd now owns 1,530 shares of the biotechnology company’s stock worth $74,000 after buying an additional 1,383 shares during the last quarter.

About AnaptysBio

AnaptysBio, Inc is a clinical-stage biotechnology company focused on the discovery and development of therapeutic antibody product candidates in immunology and inflammation. Founded in 2012 and headquartered in San Diego, California, AnaptysBio leverages a proprietary somatic hypermutation platform to rapidly generate and refine human antibodies with optimized efficacy and safety profiles. The company’s technology is designed to accelerate target validation and candidate selection across a range of immune-mediated conditions.

The company’s pipeline includes multiple clinical-stage programs addressing dermatological and inflammatory disorders.